MedTrace Logo

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

NCT05077956 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-08-07

No results posted yet for this study

Summary

Measure serum and cerebrospinal fluid Sema4A levels in female subjects with newly diagnosed and untreated relapsing multiple sclerosis, clinically stable relapsing multiple sclerosis receiving disease modifying therapy, relapsing multiple sclerosis receiving disease modifying therapy with breakthrough disease, or non-multiple sclerosis controls (patients without inflammatory central nervous system disease).

Conditions

Interventions

DIAGNOSTIC_TEST

Cerebrospinal and Blood Serum Semaphorin 4A Levels

Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    collaborator OTHER

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Stanley Cohan, MD, PhD · Providence Health and Services

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2023-10-25
Completion
2023-10-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05077956 on ClinicalTrials.gov